Every Mounjaro box carries the FDA's strongest warning label over thyroid tumors. It's based on rats, not people — here's exactly what the rodent studies found, and what human data have shown since.
Mounjaro's label carries a boxed warning — the FDA's highest-level caution — for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It sits at the very top of the prescribing information, above every other risk on the list.
The warning isn't based on a cluster of human cases. It comes from a required 2-year rodent carcinogenicity study, standard for this entire drug class before approval. Because of it, tirzepatide is contraindicated — not just cautioned against — for anyone with a personal or family history of MTC, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
In a 2-year study, tirzepatide caused a dose-dependent, duration-dependent increase in thyroid C-cell tumors in both male and female rats, at plasma exposures the FDA classifies as clinically relevant to human dosing.
The label states plainly: it is unknown whether Mounjaro causes thyroid C-cell tumors in humans, because whether the rodent finding applies to people "has not been determined." That single sentence is the entire basis for the warning — not proof of harm, but an open question regulators haven't closed. The same warning appears on every GLP-1 and GIP/GLP-1 label in the class, first required when liraglutide was approved in 2010.
The largest look at this question in people, led by Anton Pottegård at the University of Southern Denmark and published in Thyroid in January 2025, pooled six population-based databases covering type 2 diabetes patients from 2007 to 2023 — 92,497 GLP-1 receptor agonist users compared against 2,484,408 users of DPP-4 inhibitors. It found no increased risk of thyroid cancer associated with GLP-1 therapy.
Two caveats matter here. First, that dataset is class-wide, not tirzepatide-specific — since it stretches back to 2007, most of that exposure comes from older GLP-1 drugs, and tirzepatide (approved in 2022) contributes only a recent slice. Second, as the accompanying editorial from Mayo Clinic's Dr. Juan Brito and colleagues pointed out, the median follow-up was just 1.8 to 3.0 years — thin for a cancer with a years-to-decades latency period.
The thyroid warning on Mounjaro comes entirely from rat data — a dose-dependent rise in C-cell tumors that regulators haven't ruled out as human-relevant. The largest human study to date, spanning six countries and over 2.5 million patients, found no increased thyroid cancer signal with GLP-1 therapy — but its follow-up window is still too short to close the question.
Sources: FDA prescribing information for Mounjaro (tirzepatide) — boxed warning, Section 5.1. See full label (accessdata.fda.gov). Pottegård et al., Thyroid, 2025 (DOI 10.1089/thy.2024.0387), and Brito et al. commentary (DOI 10.1089/thy.2024.0690) — see American Thyroid Association summary.
If you or a first-degree relative has had medullary thyroid carcinoma, or you have MEN 2 — Mounjaro is off the table entirely. That's a contraindication, not a judgment call to make with your prescriber; tell them this history before starting.
For everyone else, the FDA still asks you to watch for symptoms — a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath — and report them promptly rather than waiting for a routine visit.
Current evidence doesn't give people without those risk factors a reason to avoid the drug on this basis alone. It's a reason to know the warning signs and to make sure family history comes up at your prescribing visit — not a verdict on the medication.
This article summarizes FDA prescribing information and published research for general education. It is not medical advice and does not replace guidance from your prescriber. If you have concerns about thyroid cancer risk or a personal or family history of MTC or MEN 2, discuss them with your healthcare provider before starting or continuing tirzepatide.